tickrz reports
Biogen Inc (BIIB)
Healthcare | Drugs
338.91  0.87%
BIIB vs DRUGS SECTOR & S&P 500
VALUATION
BIIBSECTORS&P 500
P/E RATIO20.4140.521.12
EV/EBITDA RATIO12.39133.412.66
P/S RATIO6.016.52.25
P/B RATIO5.537.73.45
QUALITY
RETURN ON EQUITY27.91%15.79%13.64%
RETURN ON CAPITAL30.26%19.38%10.09%
NET MARGIN36.32%14.46%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATIO8.69%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY51%
INTEREST COVERAGE17.3x
CURRENT RATIO2.19
GROWTH
5 YR EPS GROWTH27.41%
5 YR SPS GROWTH19.33%
5 YR BPS GROWTH16.2%
Biogen Inc News
3 Pharma and Biotech Stocks to Watch Out for in 2018
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18 7 and 11 8 respectively Although the industry continued to face headwinds in the form of drug pricing scrutiny pricing
January 15, 15:11:37 UTC

Roche MS Drug Ocrevus Gets Marketing Authorization in Europe
Roche Holdings RHHBY announced that the European Commission EC has granted marketing authorization for multiple sclerosis MS drug Ocrevus The drug is approved for patients suffering from active relapsing forms of multiple sclerosis defined by clinical or imaging features and for
January 15, 14:09:55 UTC

Will 2018 Be Biogen Inc.'s Best Year Yet?
Some questions are flat out hard to answer Others are easy as can be I d put the question of whether 2018 will be Biogen s NASDAQ BIIB best year yet in the latter category I ll go on record as saying that absolutely definitely positively and undoubtedly the answer to
January 14, 15:07:43 UTC

Will 2018 Be Biogen Inc.'s Best Year Yet?
You probably don't want to bet the farm on it.
January 14, 13:18:00 UTC

Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
In 2017 Ionis Pharmaceuticals NASDAQ IONS proved its RNA antisense technology can produce a bonafide blockbuster drug Spinraza sales are firing on all cylinders right now but incoming competition might reverse the therapy s trajectory Luckily for Ionis Biogen
January 13, 22:06:29 UTC

Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
Here's why 2018 could be a banner year for this pioneering biotech and its recent spinoff.
January 13, 20:33:00 UTC

Top Stock Reports for Home Depot, CVS Health & Biogen
Top Stock Reports for Home Depot, CVS Health & Biogen
January 12, 18:33:06 UTC

Developments for Ionis Pharmaceuticals Post-3Q17
What's the Word on Ionis Pharmaceuticals This January?
January 11, 15:33:07 UTC

Biogen Trying To Close In On Key Technical Measure
Biogen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
January 11, 08:00:00 UTC

How will tax reform affect Biogen? Its CFO offered a few hints at J.P. Morgan
Big drugmakers are head over heels over the recent tax reform bill, in part because it allows them to pay a discounted tax rate on repatriated cash — that is, profits held overseas that are brought back to the U.S. Support for the legislation has emerged as a major theme of this week’s J.P. Morgan conference in San Francisco. Biogen (BIIB), the state’s largest independent drugmaker, joined the chorus of praise during a presentation on Monday. During the presentation, CFO Jeff Capello said that Biogen’s 2018 rate “should drop by a couple hundred basis points,” or a couple percent.
January 10, 23:25:08 UTC

Exploring Ionis’s 3Q17 Quarterly Revenue Trend
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.
January 10, 21:10:02 UTC

A Look at Ionis Pharmaceuticals’ January 2018 Valuation
What's the Word on Ionis Pharmaceuticals This January?A look at Ionis Pharmaceuticals
January 10, 19:35:13 UTC

Bayer and J&J win big, Microsoft lags because of Intel, Apple turns over information
Johnson & Johnson, Microsoft, Apple and Toyota are the companies to watch.
January 10, 15:43:00 UTC

Analysts’ Recommendations for Incyte in January 2018
As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.
January 10, 15:33:15 UTC

Incyte’s Collaborations and Developments in 4Q17
New Insights for Incyte Corporation as of January
January 10, 14:04:40 UTC


Biogen Inc (BIIB)
Healthcare | Drugs
338.91  0.87%

3 Pharma and Biotech Stocks to Watch Out for in 2018
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18 7 and 11 8 respectively Although the industry continued to face headwinds in the form of drug pricing scrutiny pricing
January 15, 15:11:37 UTC

Roche MS Drug Ocrevus Gets Marketing Authorization in Europe
Roche Holdings RHHBY announced that the European Commission EC has granted marketing authorization for multiple sclerosis MS drug Ocrevus The drug is approved for patients suffering from active relapsing forms of multiple sclerosis defined by clinical or imaging features and for
January 15, 14:09:55 UTC

Will 2018 Be Biogen Inc.'s Best Year Yet?
Some questions are flat out hard to answer Others are easy as can be I d put the question of whether 2018 will be Biogen s NASDAQ BIIB best year yet in the latter category I ll go on record as saying that absolutely definitely positively and undoubtedly the answer to
January 14, 15:07:43 UTC

Will 2018 Be Biogen Inc.'s Best Year Yet?
You probably don't want to bet the farm on it.
January 14, 13:18:00 UTC

Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
In 2017 Ionis Pharmaceuticals NASDAQ IONS proved its RNA antisense technology can produce a bonafide blockbuster drug Spinraza sales are firing on all cylinders right now but incoming competition might reverse the therapy s trajectory Luckily for Ionis Biogen
January 13, 22:06:29 UTC

Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
Here's why 2018 could be a banner year for this pioneering biotech and its recent spinoff.
January 13, 20:33:00 UTC

Top Stock Reports for Home Depot, CVS Health & Biogen
Top Stock Reports for Home Depot, CVS Health & Biogen
January 12, 18:33:06 UTC

Developments for Ionis Pharmaceuticals Post-3Q17
What's the Word on Ionis Pharmaceuticals This January?
January 11, 15:33:07 UTC

Biogen Trying To Close In On Key Technical Measure
Biogen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
January 11, 08:00:00 UTC

How will tax reform affect Biogen? Its CFO offered a few hints at J.P. Morgan
Big drugmakers are head over heels over the recent tax reform bill, in part because it allows them to pay a discounted tax rate on repatriated cash — that is, profits held overseas that are brought back to the U.S. Support for the legislation has emerged as a major theme of this week’s J.P. Morgan conference in San Francisco. Biogen (BIIB), the state’s largest independent drugmaker, joined the chorus of praise during a presentation on Monday. During the presentation, CFO Jeff Capello said that Biogen’s 2018 rate “should drop by a couple hundred basis points,” or a couple percent.
January 10, 23:25:08 UTC

Exploring Ionis’s 3Q17 Quarterly Revenue Trend
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.
January 10, 21:10:02 UTC

A Look at Ionis Pharmaceuticals’ January 2018 Valuation
What's the Word on Ionis Pharmaceuticals This January?A look at Ionis Pharmaceuticals
January 10, 19:35:13 UTC

Bayer and J&J win big, Microsoft lags because of Intel, Apple turns over information
Johnson & Johnson, Microsoft, Apple and Toyota are the companies to watch.
January 10, 15:43:00 UTC

Analysts’ Recommendations for Incyte in January 2018
As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.
January 10, 15:33:15 UTC

Incyte’s Collaborations and Developments in 4Q17
New Insights for Incyte Corporation as of January
January 10, 14:04:40 UTC